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Gastric cancer is the eighth most common malig-
nancy in the United States, and has an annual inci-
dence of 1 per 10 000 people. The incidence in Japan 
is approximately 78 per 10 000 [1], and it is one of the 
commonest types of gastrointestinal tumor. Survival 
of patients with gastric cancer is poor, with an overall 
5-year survival rate of 15%. The survival rate declines 
linearly with advanced stage. While patients with early 
gastric carcinoma have a 90% 5-year survival rate, only 
10% of patients with advanced gastric cancer survive 
for 5 years [2].
From 60–65% of gastric cancer patients staged 
according to conventional methods have local disease. 
However, 50–60% of these patients experience recur-
rence and die from disseminated disease. Despite 
advances in surgical techniques, these ratios have 
remained stable over the last 50 years. In general, it 
is accepted that a number of gastric carcinoma cases 
have disseminated disease that cannot be diagnosed 
by conventional screening methods. The diagnosis of 
the patients with advanced disease is usually estab-
lished during surgical exploration. It emphasizes the 
importance of the identification of useful diagnostic 
and prognostic markers for gastric cancers.
Disseminated cells from primary solid tumors are 
considered the cause of metastases formation and 
relapse of the disease. Consequently, its detection is of 
great importance for staging, prognosis and decisions 
about therapy. Transcripts of the tumor-associated 
marker carcinoembryonic antigen (CEA) and the epi-
thelial tumor marker, cytokeratin (CK)-19 have been 
used successfully to detect disseminated cancer cells. 
We have therefore aimed to investigate the combined 
use of CEA and CK19 to detect micrometastases in 
advanced gastric carcinoma patients before operation. 
We have detected circulating cancer cells in patients 
with gastric cancer using reverse transcriptase-poly-
merase chain reaction (RT-PCR) for CK-19 and CEA 
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transcripts and have explored their possible correla-
tions with prognostic parameters.
PATIENTS AND METHODS
Patients. We analysed prospectively 50 patients 
with gastric adenocarcinoma treated at Ankara On-
cology Hospital between 2002 and 2005. Abdominal 
ultrasound (US) and chest-X-ray were done for each 
patient. The Ethical Committee of Ankara Oncology 
Hospital gave approval for this study, and written 
informed consent was obtained from all patients. 
Survival periods were obtained from hospital records 
or by phone contact. In patients unavailable for phone 
contact, the last contact was recorded as the survival 
period. Peripheral blood was obtained pre-operatively 
from 50 patients, as well as from ten healthy controls.
The patients were divided into two groups: those 
with unresectable tumors (group I) and those with 
resectable tumous (group II). There were 22 (44%) 
patients in group I and 28 (56%) patients in group II. 
Age, gender, tumor localisation, stage and presence 
of signet cell formation were recorded for all patients. 
 The patients who underwent surgical resection (group 
II), lymph node (LN) status, serousal and lymphovas-
cular invasion were recorded if present.
Semi-quantitative expression of micrometastases 
by polymerase chain reaction (PCR) was as follows: 
1) no expression; 2) baseline (minimal) expression; 
3) 1+ expression; 4) 2+ expression; 5) 3+ expression; 
6) 4+ expression.
RNA preparation and RT-PCR. Total RNA was 
isolated from 300 μl of whole blood using the QIAamp 
RNA Blood Mini Kit (QIAGEN) according to the manu-
facturer’s instructions. Reverse transcription was 
performed using 100 ng to 1 μg of RNA, 50 pmol of 
oligo(dT)18 primer, 200 U of OMNISCRIPT reverse 
transcriptase (QIAGEN, USA), 40 units of rRNasin 
RNase inhibitor (Promega), and the deoxynucleotide 
triphosphates (final concentration 500 μmol/L) in a 
total volume of 20 μL. Samples were incubated at 37 °C 
for 1 h and then heated at 95 °C for 3 min. For PCR, 1 μL 
of the reverse transcription sample was used. The in-
tegrity of RNA specimens was verified by performing 
RT-PCR with the housekeeping gene glyceraldehyde 
3-phosphate dehydrogenase (GAPDH). Nested PCR 
was conducted by addition of 1 μL of complemen-
tary deoxyribonucleic acid (cDNA) to 20 μl of reaction 
mixture containing 10 mM Tris–hydrochloric acid (pH 
9.0), 50 mM potassium chloride, 2.5 mM magnesium 
chloride, 250 nM deoxynucleotid triphosphate 10 pmol 
of each outer primer, and 2.5 units of Taq DNA poly-
merase (QIAGEN, USA). The reaction mixtures were 
subjected to 35 cycles of amplification in a program-
mable thermal cycler (Perking-Elmer Cetus, USA) us-
ing the following sequence after a denaturation step at 
94 °C for 5 min: 94 °C for 30 sec, 56 °C for 30 sec and 
72 °C for 1 min, and a final extension step at 72 °C for 
10 min. A sample of 2 μl of 20-fold diluted first ampli-
fication product was further amplified using an inner 
pair of primers. The inner and outer pairs of primers 
are given in Table 1.
Table 1. The inner and outer pairs of both CEA and CK-19 primers
Primer name Sequence TM Product size
CEA outer F GGACCTATGCCTGTTTTGTCT 58 250
CEA outer R AGCAATTTTAGACTGTAGCTGTTG 57
CEA inner F GCATCTGGAACTTCTCCTGGT 61 154
CEA inner R TGCAAATGCTTTAAGGAAGAAGC 62
CK19 outer F GTTTGAGACGGAACAGGCTCT 58 425
CK19 outer R CAGCTCAATCTCAAGACCCTG 57
CK19 inner F GCAGATCGAAGGCCTGAA 61 209
CK19 inner R TGAACCAGGCTTCAGCATC 62
PCR primer sequences for each gene were designed 
to span at least one intron region to avoid amplification 
of genomic DNA. According to this design, the PCR 
products of 154 and 209 base-pairs were amplified from 
CEA and CK19 cDNAs with nested PCR, respectively. 
The total RNA extracted from col15 and SW620 cells 
was used for optimization of the PCR and as a positive 
control. Blood cells from healthy volunteers were used 
as negative controls for every PCR reaction. Each sam-
ple was subjected to electrophoresis in 1.5% agarose 
gels and stained with ethidium bromide. Samples from 
each patient were considered to have a positive score 
if any fragment showed a band of the expected size as 
positive control both for CEA and CK-19. Some PCR 
amplification products were sequenced to confirm 
the specificity of CK19 and CEA cDNA amplification 
 products. The samples were judged to be positive (from 
+ to ++++) or negative on the basis of the intensity value 
for the PCR product on the gel. Quantification of the 
expressions was based on the hypothesis that advanced 
stage tumors might present with greater amounts of 
micrometastatic tumor cells. Comparison between the 
groups was performed using this scale.
Statistical analysis. The χ2 test or Fisher’s exact 
test was used for categorical variables. Comparison 
according to age between groups was done using 
Student’s t-test. The 1 year and 2 year survival rates 
were evaluated by the Kaplan-Meier method. The 
significance of differences between the groups was 
calculated by the log-rank test. All statistical analy-
ses were performed using the programme package 
number Crucher statistical system 2004 (Kaysville, 
UT, USA), and a p value < 0.05 was considered as 
significant.
RESULTS
Characteristics of patients and surgical proce-
dures. A total of 50 patients with gastric cancer were 
included in our study; 22 (44%) females and 28 (56%) 
males, with a mean age of 60.9 years (range 42–84). 
The tumors were localized in the cardia in 16 (32%), in 
the corpus in 11 (22%), and in the antrum in 22 (44%) 
patients. One patient (2%) presented with diffuse 
gastric cancer. Signet cell formation was detected in 
18 (36%) patients.
Eleven patients in group II underwent subtotal 
gastrectomy, and total gastrectomy was applied to the 
remaining 17 patients. Total gastrectomy combined 
with partial colon resection was applied to one patient, 
and three patients underwent total gastrectomy com-
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bined with splenectomy. Fourteen patients underwent 
D2, and 5 patients underwent D3 lymph node dissec-
tion. All palpable lymph nodes were removed in the 
remaining 9 cases.
In group I, we detected peritonitis carcinomatosis 
in 12 patients, pancreatic invasion in 14, invasion of 
celiac truncus in 7, hepatic pedincle invasion in 6, Cru-
ckenberg tumor in 2 and liver metastases in 2 patients. 
The reasons for unresectability consisted of pancre-
atic invasion, celiac truncus and or hepatic pedincle 
invasion. Treatment options for unresectable tumors 
were gastroenterostomy in 10, jejunostomy in 4, and 
gastrostomy in 3 patients. Explorative laparotomy 
and biopsy were applied to 5 patients. All patients re-
ceived chemotherapy consisted of 5-fluorouracil and 
leucovorin at four weeks for 6 cycles.
Detection of CK-19 and CEA expression in pe-
ripheral blood. No amplified product was obtained 
after RT-PCR when evaluating CK19 and CEA expres-
sion in the 10 healthy controls. CK-19 expression was 
detected in 24 gastric cancer patients (48%). Expres-
sion was not observed in 26 cases (52%). In patients 
with positive expression, 11 (22%) had baseline activity, 
3 (6%) had 1+ expression, 3 (6%) had 2+ expression, 
4 (8%) had 3+ expression, and the remaining 3 (6%) 
had 4+ expression. CEA expression was detected in 
10 patients (20%), and was not observed in 40 cases 
(80%). In patients with positive expression, 2 (4%) 
had 2+ expression, 2 (4%) had 3+ expression, and 
the remaining 6 (12%) had 4+ expression (Table 2). 
Semi-quantitative expression of micrometastases by 
PCR are given in Table 3.




Negative Positive Negative Positive
Group I 13(59%) 9(41%) 22(44%) 16(79%) 6(21%) 22(44%)
GroupII 13(40%) 15(60%) 28(56%) 24(90%) 4(10%) 28(56%)
Total 26(52%) 24(48%) 50(100%) 40(80%) 10(20%) 50(100%)
Table 3. Semi-quantitative expression of CK-19 mRNA (in 24 patients) 





2+ expression 3(6%) 2(4%)
3+ expression 4(8%) 2(4%)
4+ expression 3(6%) 6(12%)
Total 24(100%) 10(100%)
Note: * number of the patients.
There was no significant difference for either of the 
markers studied (χ2 = 4.097, p = 0.536 for CK-19 and 
χ2 = 0.791, p = 0.374 for CEA). Expressions of CEA 
and CK-19 without quantification did not also reveal 
a significant difference (χ2 = 2.052, p = 0.562). The 
difference in expressions of CK-19 and CEA mRNA ac-
cording to age, gender, tumor location, and presence 
of signet cell formation were not significant (p =  0.631; 
χ2 = 0.034, p = 0.854; χ2 = 2.037, p = 0.565; χ2 = 2.063, 
p = 0.151, respectively). The degree of expression did 
not differ significantly between the groups (χ2 = 5.396, 
p = 0.145).
Serousal invasion was observed in 25 of 28 patients 
who underwent surgical resection. Lymphovascular 
invasion was detected in 18 (36%) individuals. Lym-
phatic metastases were detected in 21 (42%) of the 28 
(56%) patients in group II. In the remaining 7 patients, 
dissected lymph nodes (LNs) were free of metastases.
CK-19 was positive in 4 of 7 patients without lym-
phatic involvement. However, this difference was not 
significant (p = 0.28). CEA was negative in all patients 
without lymphatic involvement. In cases with lymphatic 
invasion CEA expression was not different from those 
without LN metastasis (χ2 = 5.483, p = 0.140). We 
compared the difference between groups without 
quantifying the number of metastatic lymph nodes, 
and the difference was also not significant (χ2  = 2.775, 
p = 0.521 for CK-19 and χ2  = 7.885, p = 0.098 for CEA). 
Consideration of parameters in group II revealed no 
significant difference according to serousal inva-
sion (p = 0.556 for CK-19 and p = 0.618 for CEA) and 
lymphovascular invasion (p = 0.247 for CK-19 and 
p = 0.335 for CEA).
Median 1 year survival in group I and group II 
was 9.5 months (range 2–24) 20 months (range 
11–29 months) respectively (p = 0.001). Median 
2 years survival in group I was 10.5 months (range 
2–24 months), and was 28.5 months (range 11–29) in 
group 2 (p = 0.001). MVI was detected in 7 cases. CK-
19 was positive in 6 of these seven patients (85.7%) 
and CEA was positive in 5 patients (71.4%) with ce-
liac truncus involvement, and both were positive in 4 
(57.1%) of them. We detected both CK-19 and CEA 
positivity in 5 patients, and in 4 of them (80%) celiac 
truncus was invaded by the tumor. Furthermore, pa-
tients with celiac truncus invasion expressed higher 
levels of micrometastases: for CEA; two patients had 
+++ expression, and three cases had ++++ expression. 
For CK-19; two patients had ++, two had +++, and the 
remaining two had ++++ micrometastatic expression. 
Patients with MVI expressed significantly higher levels 
of micrometastases compared to those without MVI (χ2 
= 12.311, p = 0.023 for CEA, χ2 = 9.844, p = 0.009 for 
CK-19). All the patients with MVI have died within 
one year. We have evaluated the survival of patients 
according to expression patterns of CEA and CK-19. 
Mean survival of patients with high levels of CEA and 
CK-19 were 11.1 months and 11.9 months, respec-
tively. Those of the remaining cases with minimal or 
no expression for CEA and CK-19 were 30.1 months 
and 29.4 months, respectively. The difference for both 
was significant (p < 0.001 for CEA and p = 0.002 for 
CK-19). Mean survival periods of patients due to the 
expression patterns were given in Table 4, survival 
curves are depicted in Fig. 1, a, b.
Table 4. Mean survival of patients according to expression patterns of 
CEA and CK-19
Time (months) (mean ± SD) Log rank 
(χ2) p valueDeath Alive
CEA Absent or low level 9.75 ± 2.18 27.52 ± 5.70 14.851 <0.001
High level 5.80 ± 3.96 20.50 ± 9.19
CK-19 Absent or low level 10.27 ± 1.27 27.48 ± 5.69 9.807 0.002
High level 5.50 ± 3.61 21.00 ± 9.90





































Fig. 1. One year survival curves of patients according to the 
expression levels of CEA (a) and CK-19 (b); χ2 (log-rank) = 14.851, 
p < 0.001 for CEA and χ2 (log-rank) = 9.807, p = 0.002 for CK-19
The sensitivity and specificity of CK-19 in  detecting 
MVI was 26.08 and 96.15%, respectively. For CEA the 
sensitivity and specificity was 50 and 95%, respec-
tively. When we consider only high titres of markers, 
sensitivity increased to 85.7% and 62.5% for CK-
19 and CEA, respectively. In combined usage of CEA 
and CK-19 for detecting MVI, sensitivity was 80%. 
Considering combined usage of high titres in detecting 
MVI, sensitivity was 100%.
Median survival of patients with MVI was 
6.7 months (95% CI: 3.554–9.875 months), and 
those of the remaining was 30.2 months (95% CI: 
26.672–33.653 months). Patients with MVI had a sig-
nificantly lower survival rates (χ2 (log-rank) = 23.324, 


















Fig. 2. One year survival curves of patients according to the 
presence of major vascular invasion. (χ2 (log-rank) = 23.324, 
p = 0.0001)
DISCUSSION
Malignant process initiates from neoplastic prolif-
eration of a cell leading to local enlargement and as the 
progression advances, lymphatic and hematogenous 
metastases occur [3]. There is still a dilemma concern-
ing the significance of detecting circulating tumor cells 
(CTC), since only a portion of CTC have the ability to 
perform adhesions and invasion. This raises the ques-
tion of whether there is a correlation between CTC and 
tumor stage, and what portion of patients with CTC 
will develop distant metastases. Detection of distant 
metastases plays a vital role in accurate staging and 
treatment of malignant tumor. For this reason, the goal 
of a screening method should be to identify individuals 
who are at high risk of developing distant metastases. 
It is common to observe cases with micrometastases 
in which conventional screening methods failed to 
demonstrate the course [4]. From this point of view, 
we investigated the role of PCR in detecting patients 
with locally advanced disease, and the correlation of 
prognostic parameters with PCR expression.
Detection of CTC by conventional haematological 
methods is both difficult and inaccurate [5, 6]. Using 
improved methods like immunohistochemistry (IHC) 
and PCR, not only the metastatic focus but only one 
metastatic cell can be identified [7–9]. Due to its great 
sensitivity, PCR can detect trace amounts (1 per 106) of 
cells in peripheral blood, lymph nodes, cerebrospinal 
fluid, and bone marrow [10]. Furthermore, microme-
tastases undetected by IHC can be detected by PCR 
[11–13]. We applied nested RT-PCR to determine the 
CEA and CK19 mRNA molecules in combination, in 
the peripheral blood of gastric cancer patients. CEA 
is commonly used as a tumor marker and CK-19 is 
expected to display some specificity for epithelial cells.
Some markers like CEA, CK-19, CK-20 and 
α-fetoprotein have been used to detect CTC and mi-
crometastases. In different series micrometastasis 
and CTC were detected in 20 to 70 percent of patients 
with gastric cancer, and stated as favourable markers 
of distant spread [10, 14, 15]. Conflicting results have 
been reported concerning the use of CK19 mRNA 
in the peripheral blood of patients with solid tumor 
due to the presence of pseudo genes and DNA con-
tamination. To avoid these problems, RNA samples 
were incubated with DNase before cDNA synthesis, 
and primers were designed on the exon boundaries 
for both genes. Our results suggest that this method 
seems to be highly specific for micrometastatic cell de-
tection because we have not detected any amplifica-
tion product for both genes in healthy donor samples. 
But expression of both genes was observed in gastric 
cancer patients (CEA in 20% and CK-19 in 48% of the 
cases). Our results emphasize the heterogeneity of 
gene expression in tumors and justify the use of more 
than one mRNA marker for tumor cell detection.
Unlike some previous studies with different tumor 
types, we were not able to find any correlation between 
CK-19 and CEA mRNA expression with prognostic 
parameters. The positivity for PCR s in our samples 
from peripheral blood was lower than those of bone 
marrow samples and lymph nodes, when compared 
with published data. A possible explanation of this 
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controversy is the phenomenon described, particularly 
in patients with breast [16] and gastric [17] cancers, 
caused by the peculiar adhesive interaction between 
metastatic epithelial cells and stromal cells. In the 
report by Bonavina and co-workers [17], the role of 
micrometastatic expression by PCR in patients with 
non-metastatic tumors of the esophagus or gastric 
cardia was evaluated. The authors found PCR positive 
expression in peripheral blood in 3 of 18 (16.6%) pa-
tients, but they could not demonstrate any correlation 
with tumor type or lymph node status. Micrometastatic 
expressions in bone marrow were detected in 14 of 
18 patients (77.7%), and it was concluded that this 
ratio agrees with data in the literature [17]. Decreased 
ratios of peripheral micrometastatic expression might 
result from the degradation caused by circulating 
lymphocytes, and disseminated tumor cells in the cir-
culation detected by RT-PCR might represent the sub-
group that are able to preserve cell-surface antigens 
from lymphocytes. Comparison of survival curves of 
patients with different micrometastatic focuses might 
lead to a better understanding of the micrometastatic 
process.
Kodera et al. [18] have investigated the role of PCR 
in detecting peritoneal disseminated tumor cells, and 
found that positive PCR results were predictive of sur-
vival even more strongly than LN metastasis (LNM) in 
patients who underwent curative surgical procedure 
for gastric carcinoma. Their results suggested that LN 
involvement correlated with peritoneal micrometas-
tases. LN micrometastases in gastric cancer patients 
have been investigated. Even if it does not parallel with 
survival, CK-20 immunostaining has been detected in 
20.7% of node negative gastric cancer patients [19], 
although the micrometastatic expression pattern af-
fected the prognosis. Moreover, detection of multiple 
individual isolated tumor cells had the worst prognosis 
[19]. Single cells and small clusters of LNM are not 
uncommon in gastric cancer. Especially in diffuse 
type gastric cancer, the neoplastic cells lose their 
intercellular adhesion molecules, and unpredictable 
lymphatic spread can occur. Therefore, micrometa-
static involvement of LN in gastric cancer is not well 
defined. Wu et al. [20] detected LNM in 10.8% of node 
negative patients assessed by routine hematoxylin and 
eosin (H&E) staining. They concluded that detection 
of cytokeratin by RT-PCR was useful for the detection 
of LNM, and that it correlated with diffuse histologi-
cal subtype and depth of tumor invasion. If we could 
detect a correlation between conventional prognostic 
parameters and micrometastases, we might be able to 
detect patients with locally advanced tumors. In other 
words, if there had been a correlation, patients with 
early gastric carcinoma who do not have micrometa-
static expression might undergo non-invasive surgi-
cal resections. Otherwise, adjuvant chemotherapy 
and antiangiogenic treatment may be necessary for 
patients with micrometastases.
The major important point of our study is the high 
percentage of micrometastases in patients with celiac 
invasion. In these patients, the levels of micrometa-
static expression were much higher than others. To the 
best of our knowledge, this is the first report showing 
that high levels of micrometastatic expression sug-
gested by the expression of both CK-19 and CEA might 
be a clue to predicting MVI in gastric cancer patients.
The imaging modalities used commonly in clinical 
staging of gastric cancer are gastroscopy, abdominal 
US, endoscopic US (EUS), computed tomography 
(CT) and occasionally positron emission tomography-
CT (CT-PET). The combination of these methods is 
crucial in making the right diagnosis as well as the 
stage and follow-up after multimodal treatment. EUS 
and CT are especially beneficial for identifying invasion 
of gastric tumor within and beyond the gastric wall to 
adjacent structures. There are a number of reports 
indicating that EUS and CT have the ability to detect the 
tumor size and involvement of lymph nodes up to 80 
and 60%, respectively [21–23]. However, disappoint-
ing reports of CT on pre-operative staging for gastric 
cancer with low accuracy in tumor size (T) and node 
(N) staging exist in the literature [24, 25]. Magnetic 
resonance imaging (MRI) yielded discouraging results 
in gastric tumor staging as compared to CT or EUS 
[26]. Even with modern multislice CT, it may not be 
possible to evaluate infiltration of the vascular struc-
tures with any certainty. There are some nonspecific 
signs, like the degree of deformity in the circumference 
of the vascular structure or more than 90° of contact 
between the tumor and the vessel wall [27]. From this 
point of view our study permitted us to conclude that 
appropriate vascular invasion might be predicted by 
the combined detection of CEA and CK-19 mRNA in 
peripheral blood of gastric carcinoma patients.
We did not observe a significant correlation be-
tween the presence of circulating tumor cells and 
stage, LNM and serousal invasion. We had only one 
case of early gastric carcinoma, all the remaining 
patients had at least subserousal invasion. In the pres-
ent series early gastric cancer is infrequent. If we had 
more patients with early gastric carcinoma, we might 
be able to exclude the significance of the expression of 
micrometastases within this subgroup, and we believe 
that our results might then be different.
In the future, staging systems will have to provide 
specific information on the biological properties of 
residual cancer cells in order to provide more ex-
act prognostic estimates and guide patients to an 
 individually tailored multimodal treatment. However, it 
should not be forgotten that any cancer cell detected 
in peripheral blood may not be able to metastasize, 
and the significance of micrometastatic cell detec-
tion remains to be proven by multicentre prospective 
randomized trials with long-term follow-up.
In conclusion, pre-operative combined nested RT-
PCR for CK-19 and CEA (if both are positive) might 
predict MVI and thereby avoid the morbidity of invasive 
interventions like angiography. We believe that this 
procedure is minimally invasive and cost-effective, 
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and could be the method of choice for pre-operative 
evaluation of local invasion in gastric cancer.
ACKNOWLEDGEMENTS:
The authors would like to thank International 
Science Editing for their assistance with revision of 
this manuscript.
REFERENCES
1. DeVita Jr VT. Cancer. In: DeVita Jr VT, S Hellman, 
ST Rosenberg, eds. Cancer of the stomach. Philadelphia: JB 
Lippincott Comp, 1993; 765–96 pp.
2. Ming SC. Pathology of the gastrointestinal tract. In: 
Ming SC, Goldman H, eds. Adenocarcinoma and other ma-
lignant epithelial tumors of the stomach. Philadelphia: WB 
Saunders, 1992; 584–617 pp.
3. Diel IJ, Kaufman M, Goerner R, et al. Detection of 
tumor cells in bone marrow of patients with primary breast 
cancer: a prognostic factor for distant metastasis. J Clin Oncol 
1992; 10: 1534–9.
4. Kell MR, Winter DC, O’Sullivan GC. Biological 
 behaviour and clinical implications of micrometastases.  Br J 
Surg 2000; 87: 1629–39.
5. Ridell B, Landsy K. Incidence and histopathology of 
metastases of mammary carcinoma in biopsies from the pos-
terior iliac crest. Cancer 1979; 44: 1782–8.
6. Ingle JN, Tormey DC, Tan HK. The bone marrow 
 examination in breast cancer. Cancer 1978; 41: 670–74.
7. Coombes RC, Dearnaley DP, Redding WH. Protides of 
the biological fluids. In: Peeters H, ed. Micrometastases in 
breast cancer. Oxford: Pergamon, 1983; 31: 317–23.
8. Dearnaley DP, Sloane JP, Ormerod MG, et al. Increased 
detection of mammary carcinoma cells in marrow smears 
using antisera to epithelia membrane antigen. Br J Cancer 
1981; 44: 85–90.
9. Dearnaley DP, Ormerod MG, Sloane JP. Detection of 
isolated mammary carcinoma cells in marrow of patients with 
primary breast cancer. JR Soc Med 1983; 76: 359–64.
10. Sakakura C, Takemura M, Hagiwara A. Overexpression 
of dopa decarboxylase in peritoneal dissemination of gastric 
cancer and its potential as a novel marker for the detection of 
peritoneal micrometastases with real-time RT-PCR. British J 
Cancer 2004; 90: 665–71.
11. Noguchi S, Aihara T, Nakamori S, et al. The detection 
of breast carcinoma micrometastases in axillary lymph nodes 
by means of reverse transcriptase-polymerase chain reaction. 
Cancer 1994; 74: 1595–600.
12. Mattano LA, Moss TJ, Emerson SG. Sensitive detec-
tion of rare circulating neuroblastoma cells by the RT-PCR. 
Cancer Res 1992; 52: 4701–5.
13. Zigeuner RE, Riesenberg R, Pohla H. Immunomag-
netic cell enrichment detects more disseminated cancer cells 
than immunohistochemistry in vitro. J Urol 2000; 164: 1834–7.
14. Schmidt P, Thiele M, Rudroff C, et al. Detection of 
tumor cells in peritoneal lavages from patients with gastro-
intestinal cancer by multiplex reverse transcriptase PCR. 
Hepatogastroenterology 2001; 48: 1675–9.
15. Kakeji Y, Maehara Y, Shibahara K. Clinical significance 
of micrometastases in bone marrow of patients with gastric 
cancer and its relation to angiogenesis. J Gast Can 1999; 2: 
46–51.
16. Datta JH, Adams PT, Drobyski WR. Sensitive detection 
of occult breast cancer by the reverse transcriptase polymerase 
chain reaction. J Clin Oncol 1994; 12: 475–82.
17. Bonavina L, Soligo D, Quirici N. Bone marrow-disse-
minated tumor cells in patients with carcinoma of the esopha-
gus or cardia. Surgery 2001; 129: 15–22.
18. Kodera Y, Nakanishi H, Ito S. Quantitative detection 
of disseminated free cancer cells in peritoneal washes with 
real-time reverse transcriptase polymerase chain reaction. Ann 
Surg 2002; 235: 499–506.
19. Lee HS, Kim MA, Yang HK. Prognostic implica-
tion of isolated tumor cells and micrometastases in regional 
lymph nodes of gastric cancer. World J Gastroenterol 2005; 
11: 5920–25.
20. Wu ZY, Zhan WY, Li JH. Expression of E-cadherin 
in gastric carcinoma and its correlation with lymph node 
micrometastasis. World J Gastroenterol 2005; 11: 3139–43.
21. Ang TL, Ng TM, Fock KM, et al. Accuracy of endo-
scopic ultrasound staging of gastric cancer in routine clinical 
practice in Singapore. Chin J Dig Dis 2006; 7: 191–6.
22. Kim JH, Eun HW, Goo DE, et al. Imaging of various 
gastric lesions with 2D MPR and CT gastrography performed 
with multidetector CT. Radiographics 2006; 26: 1101–18.
23. Hur J, Park MS, Lee JH, et al. Diagnostic accuracy of 
multidetector row computed tomography in T- and N staging 
of gastric cancer with histopathologic correlation. J Comput 
Assist Tomogr 2006; 30: 372–7.
24. Kirk SJ, Moorehead RJ, McIlrath E, et al. Does 
preoperative computed tomography scanning aid assessment 
of oesophageal carcinoma? Postgrad Med J 1990; 66: 191–4.
25. Andaker L, Morales O, Hojer H, et al. Evaluation of 
pre-operative computed tomography in gastric malignancy. 
Surgery 1991; 109: 132–5.
26. Palmowski M, Grenacher L, Kuntz C, et al. Magnetic 
resonance imaging for local staging of gastric carcinoma: re-
sults of an in vitro study. J Comput Assist Tomogr 2006; 30: 
896–90.
27. Fiore D, Baggio V, Ruol A, et al. Multimodal imaging 
of esophagus and cardia cancer before and after treatment. 
Radiol Med 2006; 111: 804–17.
Copyright © Experimental Oncology, 2010
